Elevated Levels of IL-18 in Plasma and Skeletal Muscle in Chronic Obstructive Pulmonary Disease

Petersen, Anders Højgård; Penkowa, Milena; Iversen, Martin; Frydelund-Larsen, Lone; Andersen, Jesper L.; Mortensen, Jann; Lange, Peter; Pedersen, Bente Klarlund

doi:10.1007/s00408-007-9000-7

Cited by 77 publications

(57 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the presence of a degree of increased inflammatory markers in circulation is demonstrated [7], it is still unclear whether a similar local inflammatory process is present in peripheral skeletal muscles and might thus contribute to muscle fibre-type shift, decreased angiogenesis and eventual muscle wasting and cachexia. The relevance of this question is reflected in a series of recent studies which specifically addressed this point [13,14,15,16]. Furthermore, systemic effects of COPD were correlated with altered plasma levels of hormones [such as cortisol, leptin, ghrelin and insulin-like growth factor-1 (IGF-1)] during increased inflammation and catabolism [17, 18].…”

Section: Introductionmentioning

confidence: 99%

Increased Serum Inflammatory Markers in the Absence of Clinical and Skeletal Muscle Inflammation in Patients with Chronic Obstructive Pulmonary Disease

Piehl-Aulin

Jones²,

Lindvall³

et al. 2009

Respiration

View full text Add to dashboard Cite

Background: Muscle wasting and cachexia are common occurrences in patients with chronic obstructive pulmonary disease (COPD). Objectives: The current study aimed to investigate markers of inflammation in the circulation and skeletal muscle that might be associated with development of muscle wasting. Methods: Three groups of patients with mild, moderate and severe COPD and matched healthy controls were recruited. Serum levels of C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), IL-6, IL-8, TNF-α, cortisol, insulin-like growth factor 1 (IGF-1), leptin and ghrelin were analysed. Skeletal muscle inflammation was investigated microscopically using a panel of antibodies and standard staining for inflammatory cell infiltration. Results: All COPD patients were clinically stable, with no sign of inflammation and normal CRP values. Compared to controls, significantly increased hs-CRP levels were observed in all COPD patient groups. Significant rises in IL-6 levels were first observed in moderate COPD, while IL-8 levels were significantly elevated at the late severe stage. Circulating levels of TNF-α, cortisol, IGF-1, leptin and ghrelin were similar to control levels. No microscopic signs of skeletal muscle inflammation were observed. Conclusion: Our results identify hs-CRP as an early marker of inflammation that is significantly increased in the circulation even in mild COPD. Serum interleukin levels appear to be increased with disease progress. These changes were manifested in the absence of any clinical signs of disease exacerbation, evidence of skeletal muscle inflammation or hormonal changes.

show abstract

Section: Introductionmentioning

confidence: 99%

Increased Serum Inflammatory Markers in the Absence of Clinical and Skeletal Muscle Inflammation in Patients with Chronic Obstructive Pulmonary Disease

Piehl-Aulin

Jones²,

Lindvall³

et al. 2009

Respiration

View full text Add to dashboard Cite

show abstract

“…01. the expression of IFN-γ [7] . Another study showed [8,9] that IL-18 can inhibit a variety of tumors, the production of malignant ascites, and can prevent tumors from metastasizing to the lung or from infi ltrating into surrounding tissues, and, as a result, can extend the survival time. Furthermore, the anti-tumor activity of IL-18 is not dependent on internal factors of IL-12 and IFN-γ [10] .…”

Section: Discussionmentioning

confidence: 98%

Clinical significance of serum IL-18 and IL-18BP in patients with benign or malignant primary liver tumors

Guan

Liao

Lou

et al. 2009

Clin. Oncol. Cancer Res.

View full text Add to dashboard Cite

OBJECTIVETo study the relationship between the serum levels of IL-18 and IL-18BP in the development and growth of primary liver cancer, benign liver tumors and liver cirrhosis and to determine the value of serum IL-18 and IL-18BP in the diagnosis of primary liver cancer. METHODS The serum levels of IL-18 and IL-18BP in 36 patients with primary hepatic carcinoma (PHC) were detected. Eighteen patients were diagnosed with various benign liver tumors and 21 patients with cirrhosis of liver (LC), determined by using an ELISA assay. The serum levels of AFP in 36 patients with primary liver cancer were examined. The relationship among levels of serum IL-18, IL-18BP and AFP in the primary liver cancer was explored. RESULTS The sIL-18 levels in PHC were signifi cantly lower than in control group, the benign liver tumor group and the LC group. The sIL-18BP in PHC was signifi cantly higher than that in control group, benign liver tumor group and LC group (P < 0.001). There was a close correlation between the levels of IL-18, IL-18BP and clinical stage in PHC: the later clinical stages had lower levels of IL-18 and higher levels of IL-18BP while the earlier clinical stages had higher levels of IL-18 and lower levels of IL-18BP. There was a negative correlation between serum levels of IL-18 and AFP in the PHC group (r = -0.7152, n = 36, P < 0.01), and there was a positive correlation between serum levels of IL-18 BP and AFP in the patients with PHC (r = 0.6315, n = 36, P < 0.01). The IL-18 and IL-18BP in the patients with various benign liver tumors or LC were significantly higher than those in control group. The differences were statistically signifi cant (P < 0.01). CONCLUSION Serum levels of IL-18 and IL-18BP can reflect the immune function of patients with primary liver cancer, with various benign liver tumors or with LC and can also be indicative of the clinic stage of primary liver cancer. It can be used to assist in making a diagnosis and in determining the clinical stage of PHC. Detecting AFP concurrently can help make the diagnosis of primary liver cancer more precise. KEY WORDS: benign-malignant primary liver tumor, primary hepatic carcinoma (PHC), liver cirrhosis (LC), serum interleukin 18 (sIL-18), serum interleukin 18 link albumen (sIL-18BP)

show abstract

“…Its relationship to loss of muscle mass or strength, however, is not clearly defined. Although inflammation-related proteins in plasma, e.g., TNF-␣ (76 -78), IL-6 (76 -80), C-reactive protein (CRP) (76,78,80,81), and muscle, e.g., TNF-␣ (82), have often been demonstrated to be higher in patients with COPD compared with healthy controls, other reports indicated the contrary (22,72) or showed no difference between these groups (9,72,83). Similarly, nuclear transcription factor-␤ (NF-B) DNA-binding activity and inducible nitric oxide synthase have been found in one study to be higher in COPD patients with lower body mass index than those with higher body mass index (84), whereas another study reported no difference in inducible nitric oxide synthase levels in relationship to body mass in these patients (82).…”

Section: Relationship Between Inflammation and Muscle Dysfunction In mentioning

confidence: 96%

“…The inflammatory response can be detected early as reflected by an increased number of circulating leukocytes and cytokines in the plasma during some exercise stimuli (7). If the exercise stimulus is not excessive, a cellular and mediator response consistent with an anti-inflammatory and immunoregulatory benefit is induced (8,9). In the event of injurious exercise, which often has either an eccentric (lengthening) or an unaccustomed component, a proinflammatory response seems to dominate initially, followed by a later phase of regeneration and repair (7,10).…”

mentioning

confidence: 97%

Skeletal muscle response to inflammation—Lessons for chronic obstructive pulmonary disease

Reid

Rurak

Harris

2009

Critical Care Medicine

View full text Add to dashboard Cite

To describe how inflammation affects muscle adaptation and performance in people with chronic obstructive pulmonary disease. In chronic obstructive pulmonary disease, an increasingly sedentary lifestyle is a primary contributor to muscle dysfunction that results in a loss of mobility and independence and, ultimately, mortality. Given the systemic chronic inflammation and profound limb muscle atrophy in chronic obstructive pulmonary disease, it is tempting to speculate that the inflammatory process is deleterious to skeletal muscle. In healthy people, however, the inflammatory process initially is dominated by a destructive phase that is tightly regulated and modulates a reparative, regenerative phase. Although the inflammatory process and associated oxidative stress is more closely connected to muscle wasting in animal models of chronic obstructive pulmonary disease, the causative role of inflammation toward muscle atrophy and weakness in people with chronic obstructive pulmonary disease has not been definitively shown. Anti-inflammatory interventions aimed toward tempering muscle wasting and weakness in chronic obstructive pulmonary disease may not prove to be beneficial because of longer-term disruption of the regeneration of muscle tissue. Temporally and spatially targeted interventions aimed toward ameliorating oxidative stress, such as antioxidants, nutritional supplements, and chronic exercise training, may optimize outcomes toward maintaining muscle mass and performance.

show abstract

Elevated Levels of IL-18 in Plasma and Skeletal Muscle in Chronic Obstructive Pulmonary Disease

Cited by 77 publications

References 51 publications

Increased Serum Inflammatory Markers in the Absence of Clinical and Skeletal Muscle Inflammation in Patients with Chronic Obstructive Pulmonary Disease

Increased Serum Inflammatory Markers in the Absence of Clinical and Skeletal Muscle Inflammation in Patients with Chronic Obstructive Pulmonary Disease

Clinical significance of serum IL-18 and IL-18BP in patients with benign or malignant primary liver tumors

Skeletal muscle response to inflammation—Lessons for chronic obstructive pulmonary disease

Contact Info

Product

Resources

About